A Phase 1/2, open-label, multicenter study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of PC14586 in patients with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation.
Principal Investigator
Dott.ssa Vanesa Gregorc
Contact Information for Access
Phase
FASE II
Status
ATTIVO
Objective of the study
The objective of the study is to evaluate the efficacy and tolerability of treatment with the drug PC14586.
Multiple Cancers:
Ovarian
Breast
Endometrial
Pathologies
Breast Cancer , Gynecologic cancers (gynecological tumors)
Medication
PC14586 (a specific activator for the mutated p53 Y220C protein).
Who is eligible to participate in the study?
Patients who are 18 years of age or older and meet the study’s eligibility criteria may participate in this study.
Patients with advanced and/or metastatic solid tumors who have a TP53 Y220C mutation.
Back to search page